Message-ID: <4942098e6ea2cc6c1c1267041de1215c@plaintextures.com> Date: Sat, 30 Dec 2023 13:10:54 +0000 Subject: interleukin-2 human, il-2, recombinant& =?utf-8?Q?=D0=BA=D1=83=D0=BF=D0=B8?= =?utf-8?Q?=D1=82=D1=8C_=D0=BE=D0=BD=D0=BB=D0=B0=D0=B9=D0=BD_=D0=B2_?= =?utf-8?Q?=D0=B8=D0=BD=D1=82=D0=B5=D1=80=D0=BD=D0=B5=D1=82?= =?utf-8?Q?-=D0=BC=D0=B0=D0=B3=D0=B0=D0=B7=D0=B8=D0=BD=D0=B5_=D1=85=D0=B8?= =?utf-8?Q?=D0=BC=D0=BC=D0=B5=D0=B4?= From: LavillDot To: support@plaintextures.com MIME-Version: 1.0 Content-Type: text/plain; charset=utf-8 Content-Transfer-Encoding: quoted-printable pres= t antigen chtf8 =D0=BA=D1=83=D0=BF=D0=B8=D1=82=D1=8C =D0=BE=D0=BD=D0=BB= =D0=B0=D0=B9=D0=BD =D0=B2 =D0=B8=D0=BD=D1=82=D0=B5=D1=80=D0=BD=D0=B5=D1= =82-=D0=BC=D0=B0=D0=B3=D0=B0=D0=B7=D0=B8=D0=BD=D0=B5 =D1=85=D0=B8=D0=BC= =D0=BC=D0=B5=D0=B4 =20 Tegs: interleukin-2 human, il-2, recombinant, =D0=BA=D1=83=D0=BF=D0= =B8=D1=82=D1=8C =D0=BE=D0=BD=D0=BB=D0=B0=D0=B9=D0=BD =D0=B2 =D0=B8=D0=BD= =D1=82=D0=B5=D1=80=D0=BD=D0=B5=D1=82-=D0=BC=D0=B0=D0=B3=D0=B0=D0=B7=D0= =B8=D0=BD=D0=B5 =D1=85=D0=B8=D0=BC=D0=BC=D0=B5=D0=B4 =20 interleukin-2 human, il-2, recombinant, =D0=BA=D1=83=D0=BF=D0=B8=D1= =82=D1=8C =D0=BE=D0=BD=D0=BB=D0=B0=D0=B9=D0=BD =D0=B2 =D0=B8=D0=BD=D1=82= =D0=B5=D1=80=D0=BD=D0=B5=D1=82-=D0=BC=D0=B0=D0=B3=D0=B0=D0=B7=D0=B8=D0= =BD=D0=B5 =D1=85=D0=B8=D0=BC=D0=BC=D0=B5=D0=B4 =20 interleukin-2 human, il-2, recombinant& =D0=BA=D1=83=D0=BF=D0=B8=D1= =82=D1=8C =D0=BE=D0=BD=D0=BB=D0=B0=D0=B9=D0=BD =D0=B2 =D0=B8=D0=BD=D1=82= =D0=B5=D1=80=D0=BD=D0=B5=D1=82-=D0=BC=D0=B0=D0=B3=D0=B0=D0=B7=D0=B8=D0= =BD=D0=B5 =D1=85=D0=B8=D0=BC=D0=BC=D0=B5=D0=B4 =20 =20 prest antigen chtop =D0=BA=D1=83=D0=BF=D0=B8=D1=82=D1=8C =D0=BE=D0=BD=D0= =BB=D0=B0=D0=B9=D0=BD =D0=B2 =D0=B8=D0=BD=D1=82=D0=B5=D1=80=D0=BD=D0=B5= =D1=82-=D0=BC=D0=B0=D0=B3=D0=B0=D0=B7=D0=B8=D0=BD=D0=B5 =D1=85=D0=B8=D0= =BC=D0=BC=D0=B5=D0=B4 https://chimmed.ru/products/prest-antigen-chtop-id= =3D3959362